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Biomarkers and Pediatric Environmental Health
Bertram Lubin and Rachel Lewis
Children's Hospital Oakland Research Institute, Oakland, California
It is now possible to identify biochemical and/or cellular changes in humans due to exposure to an environmental toxin. These changes are called
biomarkers and are currently used in research studies to identify individuals exposed to specific toxic substances. Advances in the field of biomarker
technology may have important implications for the detection, prevention, and treatment of certain diseases in children. This technology may enable
physicians to screen children who have no clinically detectable illness for evidence of exposure to specific toxins. Such information could lead to
implementation of preventive measures and development of new therapeutic strategies. However, several important issues, including potential
adverse consequences resulting from the widespread use of this technology, must be considered prior to its utilization within a clinical setting.
Leaders of the pediatric and public health communities should recognize the paucity of scientific data in the pediatric environmental health area, and
new approaches to this important aspect of child health should be developed. This article will address several of the issues involved in pediatric
environmental health and consider questions that should be answered as the potential for technology transfer becomes a reality. - Environ Health
Perspect 103(Suppl 6):99-104 (1995)
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Introduction
A variety of technical advances have
enabled scientists to identify specific
changes in humans at the molecular and
cellular levels that are secondary to expo-
sure to a particular environmental toxin.
Alterations in DNA, changes in protein
structure, metabolites in urine or blood,
and other "footprints" of toxic exposure
can now be recognized and are being used
as research tools in molecular epidemiology
to identify and track toxic exposures. These
molecular or biochemical changes are
called biomarkers. As technical advances in
the field ofmolecular genetics are made, it
may become possible to detect biomarkers
at the DNA level that predict susceptibility
to environmental toxins.
The use ofthese biomarkers in a clinical
setting could facilitate the diagnosis of con-
ditions in children that occur as a result of
exposure to specific toxic substances.
Application of this technology should
enable the physician to include specific
environmental toxic exposures within the
differential diagnosis of childhood illnesses
such as failure to thrive, chronic dermato-
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logic conditions, respiratory complaints,
altered susceptibility to infection, and per-
haps even leukemia. The identification ofa
specific biomarker should help to confirm
that a child has been exposed to a particular
toxin and may provide a tool to monitor
either the effects ofthe toxin or the effects
oftherapy. Biomarkers may have especially
useful applications for regular screening of
children living in environmentally haz-
ardous areas (1).
In this article we will discuss several
environmental health issues in which the
distinction between child and adult is
crucial. We will also discuss questions that
must be addressed prior to utilization of
biomarker technology within a pediatric
clinical setting. We will emphasize the
need for research and education in the area
ofpediatric environmental health and will
present the concept of a comprehensive
pediatric environmental health program as
a model for pursuing these goals.
The Child Is Not a
Small Adult!
Pediatrics is a distinct field ofmedicine. It
is based upon the recognition that the child
is not a small adult. Indeed, the child has
unique metabolic and physiologic pathways
that are distinct from those described in
adults. Many of these differences are the
result ofdevelopmental changes that are
initiated during fetal life and continue
through adolescence. Some ofthese differ-
ences between children and adults are:
* different metabolic pathways
* increased respiratory rate
* rapid lung growth
* long life expectancy (development of
latent disease)
* high rates ofactivity
* diet
* natural curiosity
* more time spent near floor level, and
* pica behavior.
The clinical manifestations of diseases in
children, even when they are due to similar
agents and affect similar organ systems, are
often quite different from those in adults.
Unfortunately, the differences between
children and adults have not received ade-
quate attention in the field ofenvironmen-
tal health. This point was repeatedly
emphasized throughout the recent confer-
ence on Preventing Child Exposures to
Environmental Hazards: Research and
Policy Issues (Washington, DC, 18-19
March 1994). The lack ofappreciation for
the physiologic differences between chil-
dren and adults has resulted in the devel-
opment ofenvironmental safety standards
that continue to permit substantial risks to
children. Even when we consider toxins
more likely to affect children than adults,
we find that environmental safety stan-
dards such as those for pesticides do not
always take into account differences in the
size, intake, respiratory, or metabolic char-
acteristics ofa child (2).
There appear to be many reasons why
the child is likely to be more susceptible
than the adult to the effects ofan environ-
mental toxin. Among these, the most
important is the child's inability to recog-
nize certain toxins and to avoid certain
exposures. This is especially true for infants
and toddlers. In addition, differences in
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metabolic pathways required for activation
or degradation of toxic compounds, rela-
tionships between dose and surface area or
mass, water and/or caloric intake relative to
surface area, and ability to excrete haz-
ardous substances through renal or hepato-
biliary pathways contribute to the child's
inability to tolerate doses of toxins that
might be less harmful to an adult.
It is likely that the fetus and infant are
even more susceptible to the damaging
effects of environmental toxins than the
child. For example, a number ofmetabolic
pathways required to detoxify chemicals
may be lacking in the fetus and poorly
developed in the infant. Since environmen-
tal toxins can cross the placenta, certain
chemicals may concentrate in the fetus and
cause permanent damage during critical
phases ofdevelopment. The effects ofenvi-
ronmental toxic exposure during fetal
development are likely to be greater than
those observed in adults due to the rapid
cellular changes accompanying fetal
growth. The brain, with its high lipid con-
tent, provides an ideal milieu for
hydrophobic toxic solvents, and effects on
central nervous system tissues are likely to
be amplified during this period of rapid
brain growth. The child's pulmonary phys-
iology, with rapid respiration rates and
lung growth, also lends itself to complica-
tions arising from airborne toxins (3-8).
Advances in the field of biomarker
technology could have wide application in
children's health care. As this technology is
developed, it will be important to identify
appropriate biomarkers by identifying the
types ofexposure that are most common in
children. It is ofcrucial importance to rec-
ognize that many biomarkers used to detect
changes in adults may not be applicable to
children. From the technical standpoint, for
biomarkers to be used in a clinical setting,
methods to collect samples will need to be
appropriate for the child's age as well as for
intrauterine analysis in the event ofa toxic
exposure during pregnancy.
Biomarkers as
a Research Tool
Biomarkers have been used in a number of
research programs to identify and quantify
toxins and to determine the effects of a
specific toxin on laboratory animals that
have been intentionally exposed to specific
doses of the toxic substance (9). When
used successfully, these biomarkers have
enabled investigators to identify effects of
the toxin at the molecular level and to
identify animals affected by the exposure.
However, the relationship between the
biomarker and the clinical consequences of
the exposure frequently are difficult to
establish. In some cases, the animals have
developed diseases similar to those
observed in humans at comparable expo-
sure levels. In most of the animal models
studied, though the biomarker serves to
identify an affected animal, it cannot be
used to predict the physiologic as well as
the long-term effects ofthe exposure.
In addition to their applications in
experimental systems, biomarkers have
been used in clinical and epidemiologic
research to document toxic exposures and
to investigate genetic susceptibility to envi-
ronmental toxins in humans. Though there
have been a number of studies of adults
exposed to environmental toxins, limited
environmental research has been per-
formed using biomarkers to identify
affected children. Since biomarkers can be
found using small blood samples, urine, or,
in some cases, skin, there is no reason that
this technology could not be used to evalu-
ate children who have potentially been
exposed to an environmental hazard.
However, except in cases such as lead,
radon, asbestos, and some pesticide expo-
sures, there have been very few attempts to
develop new biomarker techniques to iden-
tify toxic exposures in children (10). One
ofthe objectives ofthe authors ofthis article
is to encourage scientists working in this
field to consider the needs ofthe child and
to develop technology so that appropriate
biomarkers can be used widely in a pedi-
atric setting. Advantages of biomarker
technology include early detection oftoxic
exposure, tracking of disease treatment,
preventive screening for toxic exposure in
high-risk areas, screening during pregnancy,
and inclusion oftoxic exposure in differen-
tial diagnosis.
Molecular Medicine and
Pediatric Environmental
Health
In several areas of medicine, the applica-
tion of molecular biology techniques to
clinical problems has dramatically improved
the ability to diagnose and treat diseases in
children. Within the next decade, in addi-
tion to improved molecular methods for
DNA diagnosis, basic science advances are
likely to result in gene therapy for a num-
ber of genetic conditions affecting chil-
dren. In this section, we will briefly discuss
the impact. that this molecular technology
might have on the transfer of biomarker
technology into a clinical setting.
The list ofdiseases that can be detected
by gene analysis has increased dramatically
in the last decade and is likely to continue
to increase as a consequence of current
efforts to map the human genome. In the
pediatric field, this technology has made
possible the identification ofboth genetic
traits and genetic diseases. Newborn
screening programs have incorporated
many of these advances when the genetic
information can be used to benefit the
child, and programs like the state-man-
dated newborn screening for hemoglo-
binopathies are employed on a national
scale to diagnose and treat children born
with diseases such as sickle cell anemia and
thalassemia. It may soon be possible to
identify susceptibility to certain cancers
and atherosclerosis in screening programs.
Further development of this technology
ideally will lead us beyond the
identification ofexisting conditions to the
point where we may begin to identify
genes that render a child susceptible to a
disease or to damage caused by an environ-
mental toxin (11-15).
Intrauterine diagnosis is possible for a
variety ofgenetic diseases using molecular
techniques. Although this has not been
attempted to date, it is possible that DNA
alterations or other biomarkers consistent
with a specific environmental exposure can
be identified in cells obtained from amni-
otic fluid. This information could be used
to predict consequences in situations in
which pregnant women have been exposed
to environmental toxins. The availability of
such biomarkers could help the pediatrician
who is asked about the impact ofa specific
environmental toxin during pregnancy.
As researchers identify cancer suscepti-
bility genes, genes that determine the abil-
ity to catabolize environmental toxins, and
genes that may be altered as a consequence
ofparental exposure to environmental tox-
ins, we will be faced with decisions regard-
ing the usefulness ofthis information and
the value of incorporating screening for
these genes within existing screening pro-
grams. For genetic diseases, screening pro-
cedures have been mandated when
therapies for the disorders are recognized.
Will we have similar therapies for environ-
mental agents? Should we mandate screen-
ing for environmental agents in the
absence ofeffective therapies?
Similarly, once the capability to detect
a biomarker in the fetus is accomplished,
many new issues will have to be addressed.
Is there a therapy that can be used to pre-
vent toxicity? Can this be started in utero?
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What will be the impact of the exposure
after the child is born? Finally, should a
therapeutic abortion be considered? We
have no information on this extremely
important area and careful research studies
covering basic science, social science, and
community awareness are important to
conduct simultaneously with the develop-
ment of improved biomarker technology.
Since the basis ofpediatric medicine is pre-
vention, one would hope that we could
develop procedures to avoid environmen-
tally induced disease in susceptible popula-
tions and that we could implement these
procedures on a national level.
Although there are instances where the
transfer ofgenetic technology from the lab-
oratory to the clinic has been relatively
uncomplicated, such as those in the field of
hematology, in certain cases, especially
where susceptibility to disease is involved,
several social, legal, and medical issues arise.
These include concerns regarding access to
genetic information, use of genetic infor-
mation for purposes that might not directly
benefit individuals being tested, and avail-
ability ofservices for individuals found to
have a genetic trait or disease. It is likely
that the transfer ofbiomarker technology to
the clinical setting will raise a number of
similar questions and that resolution of
these matters will require careful analysis,
planning, and the development of new
public policies.
Pediatric Environmental
Health and the
Legal Community
Ifone reviews the medical records in many
large children's hospitals, the paucity of
information on potential environmental
toxins rapidly becomes evident. For exam-
ple, when the medical records ofchildren
evaluated for respiratory illness were
reviewed, fewer than 10% of the records
indicated that questions were asked about
exposure to passive smoke. Similarly, in
patients presenting with behavioral prob-
lems and developmental irregularities,
records seldom indicate tests for blood lead
levels or other environmental toxins,
though the symptoms have been correlated
with lead exposures in children (16,17).
This lack of attention to environmental
issues in pediatrics indicates a pervasive
skepticism among health care providers
about the need for environmental health
programs and illustrates the need to
implement education programs addressing
important issues in pediatric environmen-
tal health. To be most effective, these edu-
cational programs must be incorporated in
medical school curricula, residency train-
ing programs, and postgraduate medical
education programs.
In contrast to pediatricians, who for the
most part are skeptical of the impact of
environmental toxins on children, members
ofthe legal community are often the first to
consider that a child's illness may be sec-
ondary to an environmental toxin. When
this question is raised by a lawyer, a referral
to a physician who is knowledgeable in this
area must be made. However, very few
physicians are either capable of - or inter-
ested in-providing such a consultation.
Since physicians often question a lawyer's
motivation for a referral, only infrequently
is an evaluation actually made. A lack of
willingness to cooperate with lawyers may
increase the number ofchildren who con-
tinue to suffer from environmentally
induced diseases; and even when a consulta-
tion is given, a lack ofexpertise and experi-
ence with environmental medicine may
result in a poor evaluation. Using a bio-
marker to assist in this evaluation would
help the physician confirm that an exposure
might have caused the child's illness.
A program developed by pediatricians
and members of the legal community to
work together to address this important
issue ofchild health should be considered
as part of the larger goal of raising aware-
ness of the environmental health field.
Pediatric leaders must also investigate the
possibility of collaborating with lawyers
and working within the legal system so
that preventive environmental health mea-
sures are developed to specifically address
pediatric concerns.
TechnologyTransfer,
Environmental Health, and
Clinical Pediatrics
Given the limited awareness ofor sensitivity
to environmental issues within clinical
pediatrics, it is not surprising that technol-
ogy transfer involving use ofbiomarkers in
clinical pediatrics is quite limited. At the
present time, although a few epidemiologic
studies have been conducted on children
living near toxic dump sites, application of
biomarkers to detect environmental toxic
exposures in the clinical setting has been
primarily for lead poisoning and passive
exposure to environmental tobacco smoke
(ETS) (18-20).
The accurate measurement of blood
lead in children has provided physicians
the opportunity to identify, treat, and
potentially eliminate this environmental
hazard for children. The toxic effects of
elevated blood lead have been clearly
demonstrated, and, unlike for most envi-
ronmental hazards, standards for blood
lead have been established for children
(21,22). Screening programs based upon
blood lead measurements are widespread,
and in some areas they are mandated by
law. The acceptance and implementation
of lead screening programs in specific
communities where there is high risk of
lead exposure demonstrates that when
significant environmental health problems
are identified, political pressure spear-
headed by community organizations can
lead to the development of programs to
limit toxicity.
Unfortunately, the measurement of
blood lead poisoning requires a venous
blood sample, and contamination of the
blood sample is frequent. New technology
should be developed to screen for lead poi-
soning using a biomarker that can be
detected on a blood sample obtained by a
fingerstick method. This technology
would expand the possibility of commu-
nity-based screening, as samples could be
collected in homes without the need for a
phlebotomist or the expense of a labora-
tory visit. Furthermore, such a biomarker
could be used to monitor cellular changes
secondary to lead toxicity.
Cotinine, a metabolic product of nico-
tine, can be found in the urine ofchildren
who have been exposed to environmental
tobacco smoke (ETS). Studies ofnewborn
infants have demonstrated that cotinine
can be found in their urine when the
mother has a history ofsmoking. In this
context, cotinine can also be considered a
biomarker. Although there is considerable
evidence that ETS is toxic to children and
can lead to serious medical complications
(23-25), most pediatricians are not famil-
iar with this test and laboratories to per-
form the cotinine analysis are not readily
available. Thus children with asthma or
bronchiolitis rarely have cotinine measured
in their urine even though the correlation
between ETS and these diseases in children
is well established. This gap in technology
transfer may be due to a number offactors;
certain to be among them is the lack of
awareness on the part ofphysicians of the
value ofthis biomarker as a sign ofexpo-
sure to ETS. Technology transfer would
provide a means for expanding research
and development in the biomarker field
and would open up possibilities for wider
application of biomarkers in prevention
and treatment programs.
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Potential Adverse
Consequences of
Biomarker Identification
If and when an epidemiologic approach
utilizes biomarkers in a pediatric popula-
tion, it is important to recognize the med-
ical, psychological, and sociological
consequences of such studies. More than
any other field of medicine, use of bio-
markers to identify a child's exposure or
susceptibility to toxins can have major con-
sequences that must be considered carefully
prior to initiating a study.
Behavioral changes, abnormal growth
patterns, susceptibility to infections, skin
rashes, and a host ofother medical compli-
cations may be ascribed to environmental
toxins. However, these conditions may be
completely unrelated to the toxic agent.
Unless we are able to specifically identify a
causal relationship between the biomarker
and a disease, and have a therapy to prevent
disease onset or specifically treat manifest
disease, we must proceed cautiously with
the application of biomarkers. Further-
more, as we develop advanced technology
that can be used to study environmental
toxic exposures in children, we must also
consider research plans to determine the
impact of this information on the child
and family. For example, once a parent
hears that a child has a biomarker that
indicates exposure to an environmental
toxin, the family may perceive the child in
a different light-as disabled, frail, or dam-
aged-whether or not the relationship
between the biomarker and disease process
has been firmly established. The long-term
effects on a child's self-esteem could far
outweigh the benefits ofassessing the med-
ical risk in the first place.
As we improve our molecular capabili-
ties for identification of genes responsible
for disease, we will have to develop guide-
lines on how to use this information. What
do we say to the parent who has asusceptible
child? Will we be providing information
that will benefit the child and the family?
How we will protect this child from envi-
ronmental toxins? Will the child be able to
obtain health insurance or employment as
an adult? Will biomarkers serve only to
label the child or will they actually improve
child health? With justification, one could
ask whether procedures to identify toxic
exposures help more than they create con-
fusion. These issues, although not immedi-
ate, must be considered as we advance the
technology.
It will be equally important to consider
research protocols to determine the efficacy
ofbiomarker tests. Although the validity of
biomarkers has been documented in cases
in which adults have been exposed to cer-
tain environmental toxins, similar applica-
tions in children's health are limited. Once
this technology becomes available, the issue
ofhow to treat the child who has a bio-
marker will surface. Will the marker disap-
pear when the child is removed from the
toxic environment? Will the biomarker
cause permanent alterations in DNA and
have long-term consequences such as
malignant transformation? Only sustained
research tracking the transformation of
given biomarkers from detection through
treatment will provide insight into the role
that biomarkers will play in medicine.
Through research, some of the mystery
surrounding causal links between disease
and marker will be dispelled as long-term
follow-up tracks the biomarker and corre-
lates it with the clinical picture. Answering
questions such as these will play a signifi-
cant role in shaping the public policy that
will arise from biomarker technology in the
clinical setting.
Recommendations
PhysicianEducation
Other than pediatric programs to assess
lead poisoning, there are no recognized
centers where children can be evaluated for
medical conditions resulting from exposure
to environmental hazards. Most pediatri-
cians have no awareness ofwhat should be
considered in the evaluation ofa child who
may have been exposed to an environmen-
tal toxin. The widespread skepticism of
environmental health among pediatricians
will have an impact upon the acceptance
and use ofbiomarkers or molecular tech-
niques to identify effects ofenvironmental
toxins. A major educational effort,
endorsed by the American Academy of
Pediatrics, will be required to change this
pattern ofthinking. Educational programs
addressing pediatric environmental health
must be developed for medical school cur-
ricula, pediatric residency programs, and
perhaps pediatric fellowships. Education
programs in the community should be
developed simultaneously to inform com-
munity members about issues affecting
their children and to help them work
toward a plan to improve the environment.
Such outreach is consistent with current
political trends and should assist in the
development of laws to protect children
against environmental hazards.
Collaboration betweenPediatricians
andtheIxgal Community
The authors would like to recommend fur-
ther that pediatricians and lawyers work
together to identify environmental toxins
and their effects on children. With appro-
priate legal resources, policies and laws can
be implemented to help prevent exposures.
The confidentiality of biomarker-related
information is particularly important to
protect and studies to examine the efficacy
of these procedures should be conducted.
Questions such as whether schools, insur-
ance agencies, or potential employers will
use the information must be considered to
protect the rights of the child and family.
Since we do not yet know the long-term
medical significance ofany biomarker, how
this information is handled becomes
extremely important.
CreationofCompreensiv Pediatric
EnvironmentalHealthCenters
Because the issues and technologies associ-
ated with pediatric environmental health
are so varied, coherent approaches to tack-
ling the associated problems are vitally
important. The authors envision the cre-
ation ofcomprehensive pediatric environ-
mental health centers as a means for
coordinating multifaceted efforts to solve
pediatric environmental health issues.
Modeled after national programs such as
the Comprehensive Sickle Cell Centers,
pediatric environmental health centers
would administer tests using biomarker
technology, maintain databases of current
research and correlation between biomark-
ers and disease development, provide coun-
seling to affected children and parents,
facilitate basic and clinical research into
environmental health concerns, and act as
resource centers for community members
and pediatricians.
As a new health care plan is developed,
the opportunity to address issues in envi-
ronmental health may become very
difficult. The added costs of medical and
laboratory evaluations, and the outcome of
such programs, are difficult to determine at
this point, since there are no comprehen-
sive pediatric environmental health centers
upon which we can base cost/benefit deci-
sions. Furthermore, under managed care,
the ability to obtain laboratory tests will be
limited unless clear-cut reasons for a partic-
ular test are established. Thus, it will be
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important, as the ability to detect evidence
of environmental toxins in children is
advanced, to incorporate such testing in a
cost-effective manner so that it will be
available for children in need. This is par-
ticularly important given the socioeco-
nomic status ofmany children living under
the worst environmental conditions. It will
be important to develop protocols to evalu-
ate the costs and benefits ofcomprehensive
pediatric environmental health centers and
to determine if-and to what extent-they
will eventually reduce health care costs by
improving child health. Recommendations
for a comprehensive pediatric environmen-
tal health center include the following:
* patient service projects
* public health research
* clinical and basic epidemiology
research
* education programs
* public policy/legal analysts
* economists
* community involvement
* national database
* new pediatric environmental expo-
sure standards.
NewEpidemiological Studieswith a
Focus onPediatric Issues
Reported studies to identify the effects of
environmental toxins on children are
frequently conducted outside a pediatric
medical center and primarily involve epi-
demiologists and toxicologists. As with
other research activities funded by federal
sources, topics are often chosen that have
political impact and that respond to priori-
ties established by the scientific community.
Common problems in pediatrics that might
be secondary to environmental toxins are
frequently not included, as they do not nec-
essarily address well-recognized national pri-
orities. Furthermore, these studies may be
more complicated to perform and there is
little preliminary data demonstrating causal
relationships between toxins and pediatric
disease. Absence ofthis kind ofinformation
does not mean that it is not important, and
avenues to support these projects, perhaps as
a component oflarger studies on environ-
mental toxins, must be considered.
Relationships between pediatric cancer
and environmental toxins are among the
high priorities for research, and funding
from federal agencies, although not gener-
ous, has been provided. This area ofresearch
is very important, as it represents one ofthe
major complications secondary to an envi-
ronmental toxin. Although most studies on
cancer are ofscientific merit, performing
such research outside the mainstream of
pediatrics does not lend itself to subse-
quent incorporation of findings into a
pediatric medical center. An effort should
be made to incorporate findings from such
studies into a national agenda on pediatric
environmental health.
The most effective method for bringing
advances in technology in pediatric envi-
ronmental health into a clinical pediatric
setting is to encourage teamwork between
investigators and clinicians. Common
objectives must be identified and methods
to evaluate technology must include input
from basic and clinical investigators. Such
liaisons would fall under the aegis of the
comprehensive pediatric environmental
health centers.
Conclusions
In conclusion, the authors recommend that
national emphasis be placed on developing
comprehensive programs for pediatric eval-
uation for toxic environmental exposures,
physician education in detection and treat-
ment modalities, and basic research in the
expanding field of biomarker technology.
In conjunction with development of tech-
nology and treatment, there must be.dis-
cussion and inquiry into the ethical and
psychological issues that inevitably will be
associated with the application ofthis tech-
nology in the clinical setting, and, most
importantly, we must consider ways ofpre-
venting misuse ofdiagnostic information.
Children, because oftheir rapid devel-
opment and distinct physiologic processes,
are especially vulnerable to toxic exposures.
Research that seeks to correlate long-term
disease profiles with exposure to environmen-
tal toxins is an essential part ofthe broader
effort to prevent and treat pediatric illnesses.
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